 |
- RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, and G4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks.3
- The vaccination series consists of 3 ready-to-use
liquid doses of RotaTeq administered orally starting at 6 to
12 weeks of age, with the subsequent doses administered at
4- to 10-week intervals. The third dose should not be given
after 32 weeks of age.
Select safety information
- RotaTeq should not be administered
to infants with a demonstrated history of hypersensitivity
to the vaccine or any component
of the vaccine.
- No safety or efficacy data are available
for the administration of RotaTeq to infants who are potentially
immunocompromised
or to infants with a history
of
gastrointestinal disorders.
- Caution is advised when considering whether
to administer RotaTeq to individuals with immunodeficient
contacts.
- In clinical trials, the most common adverse events
included diarrhea, vomiting, irritability, otitis media,
nasopharyngitis, and bronchospasm.
- In post-marketing experience,
intussusception (including death) and Kawasaki disease
have been reported in infants who
have received RotaTeq.
- RotaTeq may not protect all vaccine
recipients against rotavirus.
Before administering RotaTeq, please read the Prescribing
Information
and Patient
Product Information.
RotaTeq is a registered trademark of Merck & Co.,
Inc. |
